Monoclonal anti-TNF-alpha suppresses graft vs host disease reactions in an in vitro human skin model.
Graft vs host disease (GVHD) following allogeneic marrow transplant in humans is known to be mediated in part by cytokines. Tumour necrosis factor alpha (TNF-alpha) and gamma interferon (IFN-gamma) are considered to be critical in the mechanism. A commercially produced antibody to TNF-alpha (CB0006) was tested in vitro to assess its ability to suppress mixed lymphocyte reactions (MLR). Peripheral blood mononuclear cells treated and untreated with CB0006 were also tested for their ability to elicit a graft vs host reaction (GVHR) in vitro in a human skin-explant model for GVHD. The results showed that CB0006 could inhibit mixed lymphocyte culture (MLC) proliferative responses and that in vitro antibody treated responder cells were less effective in causing GVHR in vitro skin-explant assays. CB0006 was also shown to inhibit MLC supernatant induced GVHR.
Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
A M
AM
Dickinson
L
L
Sviland
G
G
Jackson
J
J
Dunn
S
S
Stephens
S J
SJ
Proctor
D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control*; D006087:Graft vs Host Reaction / Q000187:drug effects / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D008213:Lymphocyte Activation; D007959:Lymphocyte Culture Test, Mixed; D008954:Models, Biological; D012867:Skin / Q000276:immunology* / Q000473:pathology; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D006680:HLA Antigens; D014409:Tumor Necrosis Factor-alpha